The Food and Drug Administration aims to conduct priority reviews of at least two product applications for granting over-the-counter status to intranasal formulations of naloxone, an overdose-reversal drug.
Naloxone prevents overdose deaths by binding to opioid receptors in the brain and blocking entry to competing opioids, or pushing them aside. The drug is sold in three versions: vials of injectable naloxone, auto-injectors (similar to EPIPENs) and as an intranasal spray.
Create a display name to comment
This name will appear with your comment
